ALTHX — Thx Pharma SA Share News
0.000.00%
Last trade - 00:00Brief: Theranexus H1 Net Operating Loss Widens To 4.6 Million Euros
Brief: Theranexus Obtains IND Status In The U.S. To Start Clinical Development Of BBDF 101
Brief: Theranexus End-June Cash Position Up At EUR 13.5 Mln
Brief: Theranexus FY Net Operating Loss Narrows To EUR 6.1 Mln
Brief: BBDF And Theranexus Plan To Launch Phase I-III Study With BBDF-101 For Patients With CLN3 Disease
Brief: Theranexus Is Actively Pursuing Development Of Main Programmes
Brief: Theranexus, CRNL And CERMEP Create New Laboratory
Brief: Theranexus: FDA Issues Favorable Opinion On Preclinical Development Plan Submitted By Theranexus, BBDF
Brief: Theranexus And BBDF Obtain European Orphan Medicinal Product Designation For BBDF-101 In Batten Disease
Brief: Theranexus End-Sept Available Funds At EUR 11.9 Mln
Brief: Theranexus H1 Net Operating Loss Narrows To EUR 3.4 Million
Brief: Theranexus Announces Research Collaboration With University Of Lyon
Brief: Theranexus And BBDF Obtain ODD And RPDD From FDA For BBDF-101 For Batten Disease
Brief: Theranexus End-June Cash Position At 13.3 Million Euros
Brief: Theranexus Secures EUR 3.4 Million Loan Under French State Guarantee Scheme (PGE)
Brief: Theranexus FY Operating Loss Widens To 7.4 Million Euros
Brief: Theranexus: Success Of Phase 2 Study For THN102
Brief: Theranexus Q4 Free Cash Flow Stands At 9.5 Million Euros
Brief: Theranexus Announces Clinical Results Of Phase IB Study Of Drug Candidate THN201